In plain terms: the engine's vocabulary for regulator-funding architectures where the regulated entity directly pays the regulator's operating budget through structurally-mandated user fees. Canonical instance: PDUFA 1992 + reauthorizations (~46% FDA total operating budget + ~66% human-drugs-program budget by FY2022 = industry user fees). Predicted effects: reduced regulatory evidentiary standards, shortened approval times, increased industry involvement in regulator decisions, revolving-door personnel migration without record-keeping or clearance review. Pattern recognition: look for the architecture in adjacent regulators — FAA aviation certification fees, the Federal Communications Commission (FCC) spectrum-license fees, FERC energy-project fees, NRC nuclear-licensing fees. When regulator funding is structurally dependent on regulated entity, the regulator becomes a Bounded System incapable of regulating its funder. This is the FDA-specific case of a generalizable structure.